Essay On Diabetic Titration

Good morning, ladies and gentlemen. Thank you very much for joining me today. I’m Patricia Simmons, CEO of Product Manager at Matterhorn Health. As a mentioned in a press conference a couple of months ago Matterhorn Health launched its new product the GlucoGauge a blood glucose monitor which was specifically designed with our customers in mind to provide them with the highest quality product that would easily allow them to better manage their glucose levels. Matterhorn Health is committed to quality and excellence to meet our customers’ needs and expectations, therefore research and development worked diligently for three years in making the GlucoGauge device.

This essay will focus on type 2 diabetes, which is becoming one of the fast growing chronic health conditions in the United Kingdom (UK). Approximately 700 people are diagnosed with type 2 diabetes each day in the UK (Diabetes Uk, (2014)a). It is costing the NHS about £10billion pounds each year to treat diabetes along with its complication and it is expected to rise in the next couple of years (Diabetes UK, (2014)b).

There were three things that I learned from the Diabetes Vendor Fair. The first thing that i found interesting to know was about the clinical glucose assessment tool. This tool is very small like an iPod. It is a single used devices to scan and reports glucose pattern. The doctors and nurses use this sensor applied to the back of the upper arm and activated. Then the patients will wear it home for 14 days. After that, the healthcare professional can connect the reader device to computer and get the report very easy and detail. This sensor is water resistance. Patients can do any daily activities and patients also can swim for up to 30 minutes without any damaged to the sensor. This sensor is about $60 for each patient.

You can also get cheap diabetes supplies by going directly to the manufacturer. A lot of manufacturers actually provide affordable supplies to patients with special financial needs. They commit to this to maintain a good public relations character. It will not hurt to ask so go ahead and make some inquiries.

AThe major new capability from the previous members of the animus pump family,of the Animas vibe is the continuous glucose monitor CGM integration. A CGM is a wearable device that measures glucose levels in body fluids. It is’s able to give trends, and alert young and old users a like to take action when their sugar is low or high. Before the Vibe was introduced, users would carry two separate devices which each had separate suite of software to sync with a computer and share with their health care provider. This made diabetes management difficult, and added another device to the large arsenal of things that tools that one diabetics must depend on a daily basis. The integration of the CGM and insulin pump was revolutionary, yet because it was not approved by the FDA, users were left with only inconvenient, outdated equipment .

“Worldwide, more than 284 million people have diabetes, and this number is expected to reach 439 million by 2030” (Liebl, Khunti, Orozco-Beltran and Yale, 2015, p. 13). There are several types of diabetes present throughout the population (type 1 diabetes, type 2 diabetes, and gestational diabetes) (Mayo Foundation for Medical Education and Research [MFMER], 2016). “Type 2 diabetes, once known as adult-onset or noninsulin-dependent diabetes, is a chronic condition that affects the way your body metabolizes sugar (glucose), your body 's important source of fuel” (MFMER, 2016). There is a debate about whether or not Type 2 diabetics would benefit from insulin sooner (Liebl, Khunti, Orozco-Beltran and Yale, 2015). When considering diabetes management there are several things to consider, for instance the cost of medication regimens, diabetes complications, and education on self-management (Liebl, Khunti, Orozco-Beltran and Yale, 2015).

In England alone about three million people have type 2 diabetes. It is nearly four times as common as all types of cancer combined. It is regarded by some experts as the 21st century’s primary public health threat. It accounts for approximately £9bn of the annual NHS spend, and is responsible for more than 20,000 early deaths each

Diabetes is the epidemic of the 21st century and the biggest challenge confronting Australia’s health system. The facts about diabetes in Australia are alarming. 280 Australians develop diabetes every day, that’s one person diagnosed, every five minutes. Around 1.7 million people are living with diabetes, with 500,000 people undiagnosed. There are 2.2 million Australia at high risk of developing Diabetes T2 and the estimated cost of type 2 Diabetes per year is $14.6. T2 diabetes represents 85-90% of all case of diabetes and of often manageable with healthy eating and regular physical activity.

Dr. DeFronzo and his study team write that, “This represents the only demonstration that ADA goals for glycemic control can be achieved in many type 2 diabetic patients using only rapid-acting insulin.” The authors go on to state that if additional studies confirm these findings, inhaled insulin could become an effective means of controlling blood glucose in patients with type 2 diabetes who cannot achieve adequate blood glucose control with diet and exercise alone. On September 9, 2005 a U.S. FDA panel voted to advise the FDA to approve Exubera® for use in patients with diabetes. The FDA usually follows the advice of these advisory panels and it is possible that the FDA will approve Exubera® by early 2006.

Allen, Nancy A. "Feasibility and acceptability of continous glucose monitoring and accelerometertechnology in excercising individuals with type 2 diabetes." Journal of Clinical Nursing 18 (2009): 373-381.

Patients or their parents (if they are very young) are expected to test their blood sugar regularly and give themselves (or their children) insulin shots accordingly. High quality education is crucial, because “ 95% of the disease

In early 2017, Medtronic started to market the first automatic insulin pump with a built-in glucose sensor. In the UK, researchers held in

The American Diabetes Association currently recommends that adult patients with diabetes be screened for HbA1C% multiple times each year to monitor long-term glycemic control.1 However, a number of U.S. insurance providers only pay for the cost of the test if the patient has other chronic health conditions such as hypertension and/or high cholesterol, which may result in reduced HbA1C% screening among individuals with diabetes who lack health insurance or do not qualify for reimbursement of testing costs.2 This paper assesses differences in HbA1C% screening by health care providers (HCP’s) in U.S. adults with a previous diagnosis of Type-1 or Type-2 Diabetes Mellitus who participated in NHANES during 2011-2016.

Diabetes is the fastest and largest growing health issue in New Zealand. Diabetes is a disease that has reached epidemic proportions internationally and within the New Zealand community. It is the leading cause of blindness, kidney failure and lower limb amputations. There are two main types of diabetes: type 1 (insulin-dependent diabetes mellitus) and type 2 (adult-onset diabetes mellitus). An international study carried out by a team of researchers working with the World Health Organisation had found that New Zealand has one of the highest rates of diabetes. There is over 240,000 people in New Zealand who have been diagnosed with diabetes, most having type 2, and the amount on both types is rising. If someone who has diabetes cannot keep their glucose levels in an appropriate range, they can develop a number of long term health problems including damaged vessels leading to kidney failure, blindness, and damage of the nervous system. Type 2 diabetes is an issue in my community as it can be life threatening. It is a crucial issue for New Zealand, because it has such negative impact on New Zealand’s society, including creating issues with money in New Zealand. In 2008 there was a study about the health-care costs for New Zealanders with Type 2 Diabetes. It was around $540 million and it is predicted that these costs will increase to $1.78 billion by 2021. These

Their idea is to simplify the blood test for diabetes. Diabetes is on a rise in India, to address the concern of doctor’s availability and their time, cost incurred to individual for the test and consultation. AINA- Simple easy to use mobile diagnostic mobile platform for chronic disease was introduced by Michal Depa and Sidhant Jena.